These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1124 related articles for article (PubMed ID: 9112389)

  • 1. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
    Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H
    Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
    Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
    Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
    J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of growth hormone release in common carp pituitary cells by pituitary adenylate cyclase-activating polypeptide: signal transduction involves cAMP- and calcium-dependent mechanisms.
    Xiao D; Chu MM; Lee EK; Lin HR; Wong AO
    Neuroendocrinology; 2002 Nov; 76(5):325-38. PubMed ID: 12457043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
    Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
    Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
    Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptides stimulate mitogen-activated protein kinase in the pituitary cell line GH4C1 by a 3',5'-cyclic adenosine monophosphate pathway.
    Le Péchon-Vallée C; Magalon K; Rasolonjanahary R; Enjalbert A; Gérard C
    Neuroendocrinology; 2000 Jul; 72(1):46-56. PubMed ID: 10940738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats.
    Läuffer JM; Modlin IM; Hinoue T; Kidd M; Zhang T; Schmid SW; Tang LH
    Gastroenterology; 1999 Mar; 116(3):623-35. PubMed ID: 10029621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
    Vertongen P; Delhase M; Rajas F; Trouillas J; Hooghe-Peters E; Svoboda M; Robberecht P
    J Mol Endocrinol; 1996 Jun; 16(3):239-48. PubMed ID: 8782082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-specific and developmental expression of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in rat brain.
    D'Agata V; Cavallaro S; Stivala F; Canonico PL
    Eur J Neurosci; 1996 Feb; 8(2):310-8. PubMed ID: 8714702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of novel neurotrophin-1/B-cell stimulating factor-3 (NNT-1/BSF-3) in murine pituitary folliculostellate TtT/GF cells: pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide-induced stimulation of NNT-1/BSF-3 is mediated by protein kinase A, protein kinase C, and extracellular-signal-regulated kinase1/2 pathways.
    Vlotides G; Zitzmann K; Hengge S; Engelhardt D; Stalla GK; Auernhammer CJ
    Endocrinology; 2004 Feb; 145(2):716-27. PubMed ID: 14605001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary adenylate cyclase-activating polypeptide regulation of AtT-20/D16v corticotrope cell proopiomelanocortin expression and secretion.
    Braas KM; Brandenburg CA; May V
    Endocrinology; 1994 Jan; 134(1):186-95. PubMed ID: 8275932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary adenyl cyclase-activating peptide: a hypophysiotropic factor that stimulates proopiomelanocortin gene transcription, and proopiomelanocortin-derived peptide secretion in corticotropic cells.
    Boutillier AL; Monnier D; Koch B; Loeffler JP
    Neuroendocrinology; 1994 Nov; 60(5):493-502. PubMed ID: 7845539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors.
    Lundberg P; Lundgren I; Mukohyama H; Lehenkari PP; Horton MA; Lerner UH
    Endocrinology; 2001 Jan; 142(1):339-47. PubMed ID: 11145597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.